

An overlapping kinase and phosphatase docking site regulates activity of the retinoblastoma protein

Alexander Hirschi¹, Matthew Cecchini², Rachel C Steinhardt³, Michael R Schamber³, Frederick A Dick² & Seth M Rubin³

The phosphorylation state and corresponding activity of the retinoblastoma tumor suppressor protein (Rb) are modulated by a balance of kinase and phosphatase activities. Here we characterize the association of Rb with the catalytic subunit of protein phosphatase 1 (PP1c). A crystal structure identifies an enzyme docking site in the Rb C-terminal domain that is required for efficient PP1c activity toward Rb. The phosphatase docking site overlaps with the known docking site for cyclin-dependent kinase (Cdk), and PP1 competition with Cdk-cyclins for Rb binding is sufficient to retain Rb activity and block cell-cycle advancement. These results provide the first detailed molecular insights into Rb activation and establish a novel mechanism for Rb regulation in which kinase and phosphatase compete for substrate docking.

The retinoblastoma tumor suppressor protein (Rb) regulates the cell cycle through its capacity to associate with and influence the function of a number of cellular proteins. In the best-characterized example, Rb binds and inhibits E2F transcription factors to coordinate the initiation of S phase with mitogenic signaling^{1,2}. Rb activity—namely, its competency to bind E2F—is regulated by phosphorylation in a cell cycle-dependent manner. In G0 and early G1, Rb is active and modified at relatively few phosphorylation sites. In this hypophosphorylated state, Rb sequesters E2F and recruits transcriptional corepressors and chromatin-modifying enzymes to E2F-responsive promoters to block transcription^{1,3–6}. Hyperphosphorylation of Rb by cyclin-dependent kinases (Cdks) from late G1 until mitosis inactivates Rb by dissociating these factors and results in the expression of genes required for DNA synthesis and cell-cycle progression^{1,7,8}. The enzyme protein phosphatase 1 (PP1), which is required for mitotic exit and is responsible for reversing the phosphorylation of many Cdk substrates, dephosphorylates Rb beginning in anaphase^{9–11}. PP1-dependent Rb dephosphorylation has also been observed during S and G2 in response to hypoxia and DNA damage, suggesting that it is also responsible for Rb activation under these conditions^{12,13}. The importance of phosphorylation for regulating Rb activity as a tumor suppressor is underscored by the fact that genes encoding cyclin D and p16 are frequently mutated in cancers, leading to constitutive Rb hyperphosphorylation^{14,15}.

Mechanisms for regulating Rb phosphorylation have focused on the modulation of Cdk activity^{1,2,16}. Although levels of Rb phosphorylation in the cell cycle generally coincide with levels of Cdk activity, there are circumstances, such as during mitotic exit and after DNA damage, in which Rb must be actively dephosphorylated and maintained in a hypophosphorylated state. In fact, several cancer lines have

been shown to be defective in activating Rb by dephosphorylation¹⁷. Therefore, an important mechanistic question remains regarding how phosphatase activity opposes kinase activity to control Rb phosphorylation. A stable PP1–Rb complex has been observed that is coincident with the timing of dephosphorylation in mitosis¹⁸. Nevertheless, compared to Cdks, much less is known regarding how PP1 recognizes Rb and how Rb dephosphorylation may be regulated.

In cells, PP1 activity typically arises from a complex containing the catalytic subunit (PP1c) and a variable regulatory subunit; the latter confers substrate specificity and enhances activity¹⁹. There are three mammalian isoforms of PP1c; the isoforms all contain the highly conserved catalytic domain and only differ in their unstructured N and C termini^{19,20}. Nearly all regulatory subunits and many inhibitors contain a consensus Arg-Val-x-Phe (RVxF) sequence, which binds PP1c at a site distinct from the catalytic site^{19–21}. Endogenous Rb–PP1 complexes copurify with other proteins, and an interaction between Rb and the myosin phosphatase-targeting subunit has been reported^{22,23}; these observations suggest the existence of a regulatory subunit for Rb dephosphorylation. In contrast, there have been several reports of a direct, functional complex between Rb and all three PP1c isoforms without the requirement of a targeting subunit^{24,25}. Thus, the mechanism of Rb-specific PP1 activity remains unclear.

Rb contains two structured domains known as the N-terminal and pocket domains as well as a C-terminal domain (RbC) of ~150 residues (**Fig. 1a**). RbC is necessary and sufficient for observation of an Rb–PP1c complex in cell extracts for all three PP1c isoforms^{24,25}. RbC is intrinsically disordered but adopts structure upon binding E2F-DP heterodimers²⁶ (**Supplementary Fig. 1**). Other proteins that have been shown to associate with RbC include cyclins, Skp2, c-Abl and MDM2 (refs. 27–30). In the case of cyclin A (CycA), a crystal structure

¹Department of Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, California, USA. ²London Regional Cancer Program, Children's Health Research Institute, and Department of Biochemistry, University of Western Ontario, London, Ontario, Canada. ³Department of Chemistry and Biochemistry, University of California, Santa Cruz, California, USA. Correspondence should be addressed to S.M.R. (srubin@ucsc.edu).

Received 19 October 2009; accepted 11 June 2010; published online 8 August 2010; doi:10.1038/nsmb.1868

Figure 1 Rb_{880–892} is necessary and sufficient for PP1c association. (a) Domain structure of Rb with the location of the conserved Cdk consensus phosphorylation sites. (b) Isothermal titration calorimetry (ITC) data for titration of Rb_{55–928} into PP1c. (c) Results from ITC experiments as shown in b but with RbC truncation mutants. Sample ITC data from each experiment are shown in **Supplementary Figure 2**.

reveals that a short Rb_{868–878} peptide docks to the structured CycA domain in an extended conformation³¹. This sequence contains the canonical Arg-x-Leu (RxL) sequence motif that targets Cdk-cyclins to Rb and other substrates for efficient phosphorylation^{27,32}. At present, little is known about whether these RbC binding partners are capable of interacting with Rb simultaneously or competitively, leaving their regulatory impact on Rb uncharacterized.


We examine here the RbC-PP1c association in molecular detail to understand the mechanism of Rb activation by dephosphorylation. We find that human PP1c uses its regulatory subunit-binding cleft to dock with an RVxF-like motif in RbC. The PP1c binding sequence overlaps with the previously identified RxL cyclin binding site, and the association of Rb with PP1c and Cdk-cyclin is exclusive. These results reveal an efficient regulatory mechanism, generally applicable in cell signaling, in which phosphatase and kinase activities affect phosphorylation state not only through catalysis but also through restricting access to their target substrate.

RESULTS

Rb_{870–882} is necessary and sufficient for PP1c association

To determine the precise sequence requirements for RbC-PP1c binding, we applied isothermal titration calorimetry (ITC) to quantitate binding affinity. We titrated recombinant, purified Rb proteins into recombinant PP1c (α -isoform), and we calculated dissociation constants from the resulting isotherms (**Fig. 1**). We first determined that Rb_{55–928}, which contains all of the conserved Rb domains and phosphoacceptor sites, binds PP1c with $K_d = 3.9 \pm 0.2 \mu\text{M}$ (**Fig. 1b,c**). This value is typical for enzyme-substrate binding interactions and is similar to that previously observed between an RbC peptide and CycA³¹.

We next made a series of truncation mutants and tested the affinity of these mutants for PP1c by calorimetry (**Fig. 1c** and **Supplementary Fig. 2**). Rb_{771–928} and Rb_{866–928} bind PP1c with similar affinity to that of full-length Rb, which is consistent with previous reports that RbC is sufficient for the association and phosphorylation is not



required^{24,25,33}. Titration of Rb_{889–928} into PP1c results in no detectable heat signal, indicating that the conserved residue sequence between 866 and 889 is required for binding. Using a synthetic peptide, we found that Rb_{870–882} binds PP1c with comparable affinity ($K_d = 1.2 \pm 0.4 \mu\text{M}$) to that of full-length Rb, confirming that Rb_{870–882} is necessary and sufficient for PP1c association and likely contains all of the significant interacting residues. This conserved sequence contains the CycA docking site and a Lys-Leu-Arg-Phe (KLRF) sequence that resembles the consensus RVxF motif found in PP1 regulatory subunits (**Supplementary Fig. 1**).

Crystal structure of Rb_{870–882}-PP1c

We next crystallized and solved the structure of a complex of the α -isoform of PP1c with an Rb_{870–882} peptide (**Table 1**, **Supplementary Methods** and **Supplementary Fig. 3**). The structure of PP1c in the complex is essentially identical to that observed in both the PP1c-microcystin and PP1c-tungstate complexes^{33,34}. The Rb peptide binds PP1c in an extended conformation at the hydrophobic interface of the core β -sandwich subdomain opposite the catalytic site (**Fig. 2a**). Rb binding is mediated both by main chain hydrogen bonding and




Figure 2 Structure of the Rb_{870–882}-PP1c complex. (a) RbC (brown) binds in an extended conformation and extends sheet 1 of the PP1c β -sandwich domain (cyan). Purple spheres, Mn²⁺ ions at the distant PP1c catalytic site. (b) Close-up view of the Rb_{870–882}-PP1c interface. The main chain hydrogen bonding interactions between the RbC peptide (light brown) and PP1c (cyan) are shown. (c) Hydrophobic side chain interactions between Rb_{870–882} and PP1c.




Figure 3 The RbC KLRF docking sequence is required for efficient dephosphorylation by PP1c. **(a)** RbC constructs used as substrates in the phosphatase assays. **(b)** PP1c phosphatase assay using 5 μ M 32 P-labeled phosRb₇₇₁₋₉₂₈ and phosRb₇₇₁₋₈₇₄ and 10 nM PP1c. Quenched aliquots removed from the reaction at the indicated time point are visualized with phosphorimaging. **(c)** Plot of band intensities in **b** as a function of reaction time. **(d)** Plot of initial reaction rate as a function of substrate concentration for dephosphorylation of phosRb₇₇₁₋₉₂₈ and phosRb₇₇₁₋₈₇₄. Fit of the data to a simple steady-state model indicates similar apparent K_{cat} values; however, the apparent K_M for phosRb₇₇₁₋₈₇₄ is greater. Error bars, fitting error for initial rate calculation from reaction time course data. **(e)** Analysis of docking-site mutations in the phosphatase assay described in **b** and **c**. phosRb₇₇₁₋₉₂₈ with the indicated mutation was used as a substrate at a concentration of 1 μ M with 10 nM PP1c. **(f)** Analysis of docking-site mutations in a Cdk kinase assay; 2 μ M of the indicated Rb₇₇₁₋₉₂₈ substrate was phosphorylated with Cdk2-CycA in the presence of E2F1-DP1.

hydrophobic side chain interactions (**Fig. 2b,c**). Arg876–Asp878 of Rb form a short β -strand that adds to sheet 1 of the PP1c β -sandwich subdomain. The Rb β -strand makes hydrogen bonding interactions with the edge strand of the sheet that are typical of parallel strand-strand interactions.

The other significant interactions between the Rb peptide and PP1c are made by the highly conserved hydrophobic side chains of Leu875 and Phe877 (**Fig. 2c** and **Supplementary Fig. 1**). Each inserts into a pocket within the hydrophobic core of the β -sandwich subdomain of PP1c. The PP1c β -sandwich structure and the specific side chains that contact RbC are conserved in all three mammalian isoforms of the enzyme (**Supplementary Fig. 4**). Thus, our structural data are consistent with and explain the previous observation that all of the PP1c isoforms bind Rb²⁵. Furthermore, the observation that RbC contacts PP1c at a site that is distinct from the phosphatase active site explains the observation that catalytic activity of PP1c is not required for Rb-PP1 association³⁵.

The location of the Rb peptide binding site in PP1c and the molecular interactions stabilizing the complex are nearly identical to those observed between PP1c and the RVxF motif of two PP1 targeting subunits^{20,21}. In the structure of the myosin phosphatase subunit 1 (MYPT1) bound to PP1c (isoform δ) (**Supplementary Fig. 5**), Lys37–Asp39 of MYPT1 add to the PP1c sandwich domain as a parallel β -strand, and Val36 and Phe38 of MYPT1 insert into the same hydrophobic pockets of PP1c as observed here for Leu875 and Phe877 of Rb²⁰. Notably, the occurrence of leucine in RVxF motifs is extremely rare, and mutation of the canonical valine to leucine sometimes abolishes docking motif binding³⁶. However, the similarity of contacts by RbC and MYPT1 with PP1 shows that the KLRF sequence at residues 874–877 of Rb functions as an RVxF motif.

It is noteworthy that Leu875 and Phe877 in RbC also bind to hydrophobic pockets in CycA (**Supplementary Figs. 1** and **5**)³¹. Leu875 is the leucine in the Rb RxL motif that is required for its phosphorylation^{27,31,32}. Phe877 is buried along with Leu875 in the

RbC-Cdk2-CycA structure, and both appear critical for stabilizing the observed docking interaction between kinase and substrate³¹. We found that mutation of these hydrophobic residues results in a loss of RbC affinity for PP1c and Cdk2-CycA (**Supplementary Methods** and **Supplementary Fig. 2**). These experiments verify that Leu875 and Phe877 are part of an enzyme-docking site in RbC required for association with both enzymes.

The Rb paralogs p107 and p130 also contain RxL sequences that are critical for binding to Cdk2-CycA^{31,32}. However, unlike Rb, the phenylalanine in both the p107 and p130 docking motifs directly follows the leucine (Arg–Arg–Leu–Phe (RRLF)). We found that the CycA binding motifs in both pocket proteins (p107₆₅₅₋₆₆₇ and p130₆₇₇₋₆₈₉) do not also bind PP1c (**Supplementary Fig. 2**). This result is consistent with the crystal structure, which reveals that leucine forms critical contacts with PP1c in the –2 position (relative to the phenylalanine).

PP1c docking is required for efficient RbC dephosphorylation

To examine the effects of the Rb-PP1c association on Rb-directed PP1 phosphatase activity, we developed an assay to measure Rb dephosphorylation rates. We quantitatively phosphorylated two RbC constructs, both containing seven Cdk consensus sites (**Fig. 3a**), with 32 P. After mixing substrate with phosphatase, signal intensity remained at longer time points in phosphorylated Rb₇₇₁₋₈₇₄ (phosRb₇₇₁₋₈₇₄) compared to phosRb₇₇₁₋₉₂₈ (**Fig. 3b**), indicating that deletion of the PP1c docking site in RbC results in a loss of dephosphorylation efficiency. Quantification of the signal indicates that the first-order rate constant for dephosphorylation of phosRb₇₇₁₋₈₇₄ ($k_{dephos} = 0.027 \pm 0.002 \text{ min}^{-1}$) is approximately eight times smaller than for phosRb₇₇₁₋₉₂₈ ($k_{dephos} = 0.20 \pm 0.01 \text{ min}^{-1}$) (**Fig. 3c**). We also found that a short peptide containing the KLRF sequence inhibits phosRb₇₇₁₋₉₂₈ dephosphorylation when added to the assay, further confirming that the docking site permits more efficient substrate processing (**Supplementary Fig. 6**). Analogous phosphatase assays with mutant phosRbC fragments




Figure 4 PP1c inhibits Cdk2-CycA activity toward RbC. Phosphorylation of 2 μ M Rb₇₇₁₋₉₂₈ or Rb₇₇₁₋₈₇₄ with 75 nM Cdk2-CycA in the absence and presence of a saturating concentration of PP1c-microcystin (15 μ M).

that contain only one pair of phosphorylated sites show that dephosphorylation occurs at all of the sites with kinetics that are sensitive to the presence of the PP1c docking site (**Supplementary Fig. 7**).

We performed phosphatase assays at different substrate concentrations to determine apparent steady-state kinetic parameters for dephosphorylation of the multiple RbC sites (**Fig. 3d**). The apparent k_{cat} for dephosphorylation of phosRb₇₇₁₋₈₇₄ ($k_{\text{cat}} = 140 \pm 20 \text{ min}^{-1}$) and of phosRb₇₇₁₋₉₂₈ ($k_{\text{cat}} = 160 \pm 20 \text{ min}^{-1}$) are similar. However, the apparent K_M for phosRb₇₇₁₋₈₇₄ ($K_M = 30 \pm 10 \mu\text{M}$) is greater than the apparent K_M of phosRb₇₇₁₋₉₂₈ ($K_M = 6 \pm 3 \mu\text{M}$). These results are consistent with the RbC KLRF docking sequence enhancing dephosphorylation by enabling PP1c to capture substrate and form an enzyme-substrate complex.

We next examined how mutations in the overlapping PP1c and Cdk-cyclin docking site affect enzyme activity toward Rb. In the phosphatase assay, dephosphorylation of Rb₇₇₁₋₉₂₈ that contains an F877A mutation ($k_{\text{dephos}} = 0.071 \pm 0.004 \text{ min}^{-1}$) is slower than wild type ($k_{\text{dephos}} = 0.29 \pm 0.03 \text{ min}^{-1}$) (**Fig. 3e**). Switching the position of the phenylalanine and arginine (R876F F877R) in Rb₇₇₁₋₉₂₈, which creates a docking sequence that more resembles P107 and P130, also results in a smaller first-order rate constant in the assay ($k_{\text{dephos}} = 0.067 \pm 0.006 \text{ min}^{-1}$).

To test these mutants in a kinase assay, we prepared complexes of RbC and E2F1-DP1 to mimic the physiological, active Rb substrate. In binding assays, the presence of E2F1-DP1 does not affect appreciably the affinity of either PP1c or Cdk2-CycA for RbC (**Supplementary Fig. 2**), indicating that the E2F-DP binding site in RbC does not overlap with the common enzyme-docking site. The first-order rate constant characterizing phosphorylation of wild-type RbC ($k_{\text{phos}} = 0.023 \pm 0.001 \text{ min}^{-1}$) is greater than that for the F877A mutant ($k_{\text{phos}} = 0.011 \pm 0.001 \text{ min}^{-1}$) (**Fig. 3f**). This measured kinetic difference is consistent with the Lys-x-Leu-x-Phe (KxLxF) motif at 873-877 in Rb being required for phosphorylation by Cdk2-CycA²⁷. The R876F F877R mutant ($k_{\text{phos}} = 0.024 \pm 0.001 \text{ min}^{-1}$) has

a first-order rate constant similar to that of wild type. This observation follows previous findings that Cdk2-CycA is capable of docking to both K/RxLxF (Rb-like) or K/RxLF (p107-like) sequences³¹. Our kinetic studies of docking-site mutants show that both PP1c and Cdk-cyclin utilize an overlapping docking site in Rb and indicate that the R876F F877R mutant is defective as a PP1 substrate but not as a Cdk substrate.

PP1 inhibits Cdk2-CycA activity toward Rb

Considering that both kinase and phosphatase cannot bind the required docking site together, we hypothesized that each enzyme would act as an inhibitor of the other by occluding the site. We first tested whether inactive PP1c could inhibit the phosphorylation of RbC by Cdk2-CycA in the kinase assay (**Fig. 4**). In the absence of PP1c, the first-order rate constant for Rb₇₇₁₋₉₂₈ phosphorylation ($k_{\text{phos}} = 0.0185 \pm 0.0001 \text{ min}^{-1}$) was 11 times greater than that for Rb₇₇₁₋₈₇₄ phosphorylation ($k_{\text{phos}} = 0.0017 \pm 0.0001 \text{ min}^{-1}$). We then carried out kinase reactions in the presence of saturating quantities of PP1c that was irreversibly inhibited at its catalytic site with microcystin (**Fig. 4**). The presence of PP1c-microcystin reduces the rate constant for Rb₇₇₁₋₉₂₈ phosphorylation ($k_{\text{phos}} = 0.0051 \pm 0.0001 \text{ min}^{-1}$) such that it is more similar to the rate constant for Rb₇₇₁₋₈₇₄ phosphorylation. By contrast, PP1c-microcystin has little effect on Rb₇₇₁₋₈₇₄ phosphorylation ($k_{\text{phos}} = 0.0013 \pm 0.0001 \text{ min}^{-1}$). Thus, our data indicate that PP1c directly inhibits RbC phosphorylation by Cdk2-CycA and that inhibition is independent of phosphatase activity and dependent on the presence of the KLRF docking site. We have also found, using the phosphatase assay, that Cdk2-CycA inhibits RbC-directed PP1c phosphatase activity (**Supplementary Fig. 8**).

Inhibition of Cdk access to Rb blocks cell-cycle progression

Having established that Cdk and PP1c compete for Rb access, we investigated the functional importance of this competition in the context of cell-cycle regulation. The human osteosarcoma cell line Saos-2 is deficient for Rb, and Rb re-expression leads to a strong G1 arrest³⁷. Coexpression of Cdk2-CycA abrogates this arrest through phosphorylation and inactivation of Rb^{38,39}. We used this model system to observe the effect of PP1 on Cdk regulation of Rb (**Fig. 5a**). We found that the Rb-induced arrest was overcome by Cdk2-CycA expression, and it could be largely recovered by expressing PP1c. Notably, coexpression of a catalytically inactive mutant of PP1c (PP1c H248K) also resulted in a restoration of G1 arrest. Omission of Rb from these assays abrogated the PP1c-dependent cell-cycle block, confirming that Rb is the relevant target of enzyme competition. In **Figure 5b**, the expression levels of PP1c were titrated and reveal that catalytically inactive enzyme is as potent as wild type in blocking cell-cycle advancement under conditions in which Rb expression has been reduced. Based on these cell-cycle control data, we conclude that the competition for substrate access between Cdk2-CycA and PP1c on Rb offers an efficient means to control cell proliferation beyond the catalytic regulation of phosphorylation.

We next confirmed that PP1c inhibits phosphorylation of Rb in cells, as in our kinetic analyses, in a manner that is independent of catalytic activity. We used C33A cells to test whether exogenously introduced PP1c could compete with Cdks and block Rb phosphorylation regardless of cell-cycle position effects on enzyme activity (**Fig. 5c**). Ectopically expressed Rb becomes phosphorylated in C33A cells. Expression of a dominant negative Cdk2 controls for inhibition of Rb phosphorylation in our analysis, and coexpression of Rb with Cdk2-CycA shows the maximum extent of Rb hyperphosphorylation.




Figure 5 PP1c inhibits Cdk inactivation of Rb independently of phosphatase activity. **(a)** Saos-2 cells were transfected with expression plasmids corresponding to the indicated proteins. The H248K form of PP1 is a catalytically inactive mutant. The percentage of cells in G1 is indicated for each. Error bars, s.d. from the mean from at least four experiments. **(b)** Saos-2 cells were again transfected with Cdk2-CycA, and Rb expression plasmids and cell-cycle position was analyzed by flow cytometry. The levels of expression plasmid for PP1 and the H248K mutant were titrated to compare their relative effect on an Rb-dependent arrest. **(c)** C33A cells were transfected with the expression plasmids corresponding to the indicated proteins. Rb and phosphoserine 807/811-Rb were detected by western blotting (WB). phosRb and Rb, relative migration positions of hyper- and hypophosphorylated Rb, respectively. **(d)** C33A cells were transfected with the indicated proteins, and Rb was detected as in **c**. WT, wild type. **(e)** Saos-2 cells were transfected with expression plasmids corresponding to the indicated proteins, and the analysis was conducted as in **a**. **(f)** Saos-2 cells were transfected with Rb, or the indicated Rb mutant, and Cdk2-CycA expression plasmids as in **b**. Increasing quantities of PP1c were co-transfected to assess the sensitivity of the Rb mutant to protection from phosphorylation and subsequent cell-cycle advancement out of the G1 phase.

As predicted, expression of PP1c or catalytically dead PP1c H248K inhibited Rb phosphorylation levels in a dose-dependent manner.

Our kinetic data indicate that the Rb R876F F877R mutant is a poor PP1 substrate but a good Cdk substrate. We used this mutation to study the importance of the docking site for dephosphorylation and Rb activation in cell-based assays. First, we transfected wild-type Rb and Rb R876F F877R into C33A cells with and without also transfecting PP1c (**Fig. 5d**). Coexpression of PP1c reduces the observed phosphorylation of wild-type Rb (migrates as a faster, single band), whereas the mutant Rb R876F F877R is unaffected by phosphatase expression. This observation suggests that the docking interaction observed in our crystal structure is required in cells for efficient Rb dephosphorylation by PP1.

We also tested the Rb R876F F877R mutant in the Saos-2 cell-cycle arrest assay. Expression of Rb R876F F877R in Saos-2 cells gives a less robust arrest in G1 compared to wild type, consistent with the idea that Rb activation requires docking-dependent PP1c dephosphorylation that is defective in this mutant (**Fig. 5e**). Cdk2-CycA

expression still inactivates Rb R876F F877R as expected because the kinase-docking site remains intact. We also find that, under conditions in which Rb and kinase are expressed, coexpression of PP1c is sufficient to restore the activity of wild-type Rb but is unable to reactivate phosphorylated Rb R876F F877R (**Fig. 5f**). Taken together, these data highlight a critical role for the KLR docking site in the regulation of Rb activity.

Stable Rb–PP1 complexes are coincident with Rb activation

The competition for access to Rb between PP1c and Cdk-cyclin suggests that Rb and PP1c are in a complex at times when Rb is activated by dephosphorylation. To investigate the relevance of this mechanism of cell-cycle regulation under endogenous conditions, we examined the abundance of Rb–PP1c complexes in CV-1 cells during mitotic exit and transfected Saos-2 cells that arrest in a PP1-dependent manner in early G1 (**Fig. 6**). We used CV-1 cells because synchronization experiments have shown that PP1 and Rb associate selectively in late mitosis, coincident with Rb dephosphorylation and activation in these

cells¹⁸. We first compared the relative level of the endogenous proteins in CV-1 cells with the level of transfected proteins in Saos-2 cells by applying recombinant standards (**Fig. 6a**). We found that the molar quantities of Rb in extracts from CV-1 and Saos-2 transfected cells were equivalent. Considering that the majority of Saos-2 cells are transfected in our experiments, the Rb expression level in the Saos-2 cells is no more than 2 times higher. The levels of PP1c in mitotic CV-1 cells were a little less than half as much as those of Rb, whereas the total levels of endogenous and exogenously introduced PP1c in arrested Saos-2 cells were approximately equivalent to those of Rb. These observations indicate that our transfection-based assay system closely mimics the levels of endogenous proteins under conditions where Rb is activated.




Figure 6 Abundant Rb–PP1c complexes during PP1c-dependent growth arrest. **(a)** Saos-2 cells were transfected as in **Figure 5a** to generate a PP1c-dependent arrest in early G1. CV-1 cells were released from an S-phase block, and mitotic cells were isolated by a mitotic shakeoff 16 h later. Extracts were analyzed by SDS-PAGE and western blotting (WB) to quantitate Rb and PP1c levels. Quantities of Rb and PP1c were determined by band intensities relative to a standard curve generated using recombinant proteins. The quantities are listed below each respective gel lane. **(b)** Rb was immunoprecipitated from extracts prepared as in **a**, and the quantities of Rb and associated PP1c were determined as above.

Table 1 X-ray data collection and structure model refinement statistics

	Rb ₈₇₀₋₈₈₂ -PP1c
Data Collection	
Space group	<i>P</i> 4 ₁ 2 ₁ 2
Cell dimensions	
<i>a</i> , <i>b</i> , <i>c</i> (Å)	92.95, 92.95, 192.38
Resolution (Å)	83.6–3.2
<i>R</i> _{pim} (%) ^a	5.6 (20.6)
<i>I</i> / σ <i>I</i>	18.8 (4.6)
Completeness (%)	98.2 (97.8)
Redundancy	12.3
Refinement	
Resolution (Å)	3.2
No. Reflections	13,588
<i>R</i> _{work} / <i>R</i> _{free} (%)	22.1 / 26.1
No. Atoms	4,798
Protein	4,792
Ligand/ion	6
Avg. <i>B</i> -factor (Å ²)	50.1
R.m.s. deviations	
Bond lengths (Å)	0.004
Bond angles (°)	0.789

Values in parentheses correspond to the highest-resolution shell (3.4–3.2 Å).

^a $R_{pim} = \sum_{hkl} [1/(N-1)]^{1/2} \sum_i |I_i(hkl) - I(hkl)| / \sum_{hkl} \sum_i I_i(hkl)$, where *i* indexes the *i*th measurement of reflection *hkl* and *N* indicates the total number of times a given reflection is measured.

We next immunoprecipitated Rb complexes from CV-1 and transfected Saos-2 cells and immunoblotted for bound PP1c (Fig. 6b). The amount of PP1 coprecipitated from arrested Saos-2 cells is ~30% of the total amount of immunoprecipitated Rb, indicating that one-third of Rb molecules are bound to PP1c when cells are arrested in a PP1-dependent manner. The amount of PP1c coprecipitated with Rb in CV-1 cells is ~2%; however, given that the population of CV-1 cells is actively progressing through mitosis and the limitations of synchronization by shakeoff, this measurement likely underestimates the quantity of Rb–PP1c complex that exists in a cell at the instant of Rb activation. Taken together, these experiments suggest that PP1 can form stable, abundant complexes with Rb at endogenous expression levels. These complexes attenuate the activity of Cdks by blocking their access to Rb and regulate progression through the cell cycle.

DISCUSSION

Although much attention has been paid to the inactivation of Rb by Cdk phosphorylation from G1 through mitosis, less is known regarding how Rb is activated by PP1 dephosphorylation during mitotic exit and following cellular stress. We have identified a short sequence in RbC that binds to PP1c directly and is required for efficient Rb-directed PP1 phosphatase activity. Our structural data show that the molecular interactions stabilizing RbC–PP1c are nearly identical to those observed between PP1c and its regulatory subunits. Whereas PP1c typically uses its hydrophobic binding cleft to recruit an additional subunit responsible for substrate binding, here PP1c uses the cleft to recruit Rb substrate directly^{20,21}. Although uncommon, a direct interaction between PP1c and the PP1 substrate Cdc25 has also been observed in *Xenopus laevis* embryonic extracts⁴⁰. Recent data indicate that PP1c dissociates from inhibitors following Cdk inactivation during mitosis⁹. The timing of this population of free PP1c is concurrent with the requirement to dephosphorylate Rb through a direct interaction,

and it would be interesting to explore whether other PP1 substrates are dephosphorylated at mitotic exit without a targeting subunit.

The fact that the direct enzyme-substrate association is mediated through the ‘RVxF’-binding cleft may explain why an Rb-targeting regulatory subunit has not been identified and is not necessary for Rb dephosphorylation²⁵. Although the existence of such a subunit cannot be ruled out, our data indicate that both Rb and a hypothetical Rb-targeting subunit could not both occupy the RVxF-binding cleft and that a different mode of Rb–PP1 holoenzyme assembly would be required. However, considering that multiple phosphates in varying sequence contexts must be hydrolyzed in Rb, it seems reasonable that the Rb phosphatase would not use a targeting subunit to impart a high degree of specificity. RbC closely mimics regulatory subunits in PP1 binding, and it is also tempting to speculate that Rb itself is a PP1 regulatory subunit, either sequestering nuclear PP1c from other activating subunits or regulating PP1c access to other substrates. Notably, it has been reported that RbC can act as a noncompetitive inhibitor of PP1c activity toward a generic substrate³⁵.

Our data, together with previous results, indicate that PP1c and Cdk2-CycA bind an overlapping docking site in RbC that is required in each case for efficient enzymatic activity^{27,31}. To our knowledge, this observation is the first example of a PP1c-binding sequence (RVxF or other) having an additional functional role that competes with PP1 activity. As a result of their exclusive associations with substrate, we have shown that Cdk2-CycA and PP1c can each directly inhibit the activity of the other enzyme toward Rb. This result reveals a novel mechanism for the regulation of Rb phosphorylation state in which kinase and phosphatase compete for access to substrate. Given the conservation of the RxL binding cleft in cyclin paralogs, it is assumed that the observed competition would exist between PP1 and all Cdk-cyclins that phosphorylate Rb. In contrast, the other Rb family proteins p107 and p130 do not bind PP1c; this competitive mechanism is unique to Rb.

Competition between kinase and phosphatase for controlling the phosphorylation state of a common substrate has been established as an important mechanism in cell signaling, and a theoretical framework has been crafted for how such competition can generate critical signaling properties such as sensitivity, switch-like responses and multiple steady-state outputs^{41–44}. However, few experimental observations of these properties have been reported. Our finding of a Cdk-cyclin competition with PP1c for Rb as a substrate not only provides a rare example of direct kinase-phosphatase competition but also shows that competition can be for substrate docking as well as catalysis. Notably, the presence of common kinase/phosphatase docking sites in mitogen-activated protein kinases has been observed⁴⁵, suggesting that competition for substrate binding may have a more general role in signal transduction.

In the context of Rb phosphorylation in cell-cycle control, signaling sensitivity and specificity are critical. From mitosis through G1, the capacity of PP1c to inhibit Cdk-cyclin could facilitate efficient Rb dephosphorylation in response to small changes in PP1c concentration and could prevent Rb from being promiscuously rephosphorylated by residual Cdk activity. The same holds true in response to cellular stress and cell-cycle exit, and in fact, it has been shown that Rb is dephosphorylated in response to DNA damage despite the presence of active Cdks¹³. These regulatory concepts that would serve to activate Rb are supported by our cell-cycle arrest assays. Therefore, our findings establish a biochemical mechanism through which Rb phosphorylation and function can be tightly controlled in the cell by directly competing kinase and phosphatase activities. Further study is necessary to determine what mechanisms influence the outcome of

the competition and how access of each enzyme to the docking site is controlled. Considering the observation that the association between Rb and PP1c is direct, the nuclear concentration of PP1c, free of inhibitors and other targeting subunits, is an intriguing possible factor.

METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/nsmb/>.

Accession codes. Protein Data Bank: Coordinates and structure factors for the Rb_{870–882}-PP1c complex have been deposited under code 3N5U.

Note: Supplementary information is available on the Nature Structural & Molecular Biology website.

ACKNOWLEDGMENTS

The authors acknowledge the staff at Beamline 5.0.1 of the Advanced Light Source (Lawrence Berkeley National Laboratories) and are grateful to N. Dyson (Massachusetts General Hospital) for CMV-CycA and T. Pawson (MSHRI, Toronto) for the CMV-myc-PP1c plasmid. The Rb 4.1 hybridoma developed by J. Sage was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the US National Institute of Child Health and Human Development and maintained by The University of Iowa, Department of Biology. This work is supported by grants from the Canadian Institutes of Health Research (MOP89765 to F.A.D.) and the US National Institutes of Health (R01CA132685 to S.M.R.). A.H. is supported by a US National Institutes of Health training grant (T32GM008646). M.C. acknowledges the Canadian Institutes of Health Research for an M.D./Ph.D. studentship award and the CaRTT training program. A.H. and S.M.R. thank the Santa Cruz Cancer Benefit Group for their support. F.A.D. thanks the Canadian Cancer Society for a Research Scientist Award. S.M.R. is a Pew Scholar in the Biomedical Sciences.

AUTHOR CONTRIBUTIONS

A.H., M.C., F.A.D. and S.M.R. all designed aspects of the study; A.H., M.C., R.C.S., M.R.S. and S.M.R. performed experiments; all authors analyzed data; F.A.D. and S.M.R. wrote the manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Published online at <http://www.nature.com/nsmb/>.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>.

- Dyson, N. The regulation of E2F by pRB-family proteins. *Genes Dev.* **12**, 2245–2262 (1998).
- Weinberg, R.A. The retinoblastoma protein and cell cycle control. *Cell* **81**, 323–330 (1995).
- Brehm, A. *et al.* Retinoblastoma protein recruits histone deacetylase to repress transcription. *Nature* **391**, 597–601 (1998).
- Kennedy, B.K. *et al.* Histone deacetylase-dependent transcriptional repression by pRB in yeast occurs independently of interaction through the LXCXE binding cleft. *Proc. Natl. Acad. Sci. USA* **98**, 8720–8725 (2001).
- Nielsen, S.J. *et al.* Rb targets histone H3 methylation and HP1 to promoters. *Nature* **412**, 561–565 (2001).
- Zhang, H.S. *et al.* Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. *Cell* **101**, 79–89 (2000).
- Adams, P.D. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdk. *Biochim. Biophys. Acta* **1471**, M123–M133 (2001).
- Harbour, J.W., Luo, R.X., Dei Santi, A., Postigo, A.A. & Dean, D.C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. *Cell* **98**, 859–869 (1999).
- Wu, J.Q. *et al.* PP1-mediated dephosphorylation of phosphoproteins at mitotic exit is controlled by inhibitor-1 and PP1 phosphorylation. *Nat. Cell Biol.* **11**, 644–651 (2009).
- Ludlow, J.W., Glendening, C.L., Livingston, D.M. & DeCaprio, J.A. Specific enzymatic dephosphorylation of the retinoblastoma protein. *Mol. Cell. Biol.* **13**, 367–372 (1993).
- Ludlow, J.W., Shon, J., Pipas, J.M., Livingston, D.M. & DeCaprio, J.A. The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T. *Cell* **60**, 387–396 (1990).
- Krucher, N.A. *et al.* Dephosphorylation of Rb (Thr-821) in response to cell stress. *Exp. Cell Res.* **312**, 2757–2763 (2006).
- Dou, Q.P., An, B. & Will, P.L. Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. *Proc. Natl. Acad. Sci. USA* **92**, 9019–9023 (1995).
- Classon, M. & Harlow, E. The retinoblastoma tumour suppressor in development and cancer. *Nat. Rev. Cancer* **2**, 910–917 (2002).
- Sherr, C.J. Cancer cell cycles. *Science* **274**, 1672–1677 (1996).
- Morgan, D.O. Principles of CDK regulation. *Nature* **374**, 131–134 (1995).
- Broceno, C., Wilkie, S. & Mittnacht, S. RB activation defect in tumor cell lines. *Proc. Natl. Acad. Sci. USA* **99**, 14200–14205 (2002).
- Durfee, T. *et al.* The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. *Genes Dev.* **7**, 555–569 (1993).
- Cohen, P.T. Protein phosphatase 1-targeted in many directions. *J. Cell Sci.* **115**, 241–256 (2002).
- Terrak, M., Kerff, F., Langsetmo, K., Tao, T. & Dominguez, R. Structural basis of protein phosphatase 1 regulation. *Nature* **429**, 780–784 (2004).
- Egloff, M.P. *et al.* Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. *EMBO J.* **16**, 1876–1887 (1997).
- Kiss, A. *et al.* Myosin phosphatase interacts with and dephosphorylates the retinoblastoma protein in THP-1 leukemic cells: its inhibition is involved in the attenuation of daunorubicin-induced cell death by calyculin-A. *Cell. Signal.* **20**, 2059–2070 (2008).
- Nelson, D.A., Krucher, N.A. & Ludlow, J.W. High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein. *J. Biol. Chem.* **272**, 4528–4535 (1997).
- Tamrakar, S. & Ludlow, J.W. The carboxyl-terminal region of the retinoblastoma protein binds non-competitively to protein phosphatase type 1α and inhibits catalytic activity. *J. Biol. Chem.* **275**, 27784–27789 (2000).
- Vietri, M., Bianchi, M., Ludlow, J.W., Mittnacht, S. & Villa-Moruzzi, E. Direct interaction between the catalytic subunit of protein phosphatase 1 and pRB. *Cancer Cell Int.* **6**, 3 (2006).
- Rubin, S.M., Gall, A.L., Zheng, N. & Pavletich, N.P. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. *Cell* **123**, 1093–1106 (2005).
- Adams, P.D. *et al.* Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. *Mol. Cell. Biol.* **19**, 1068–1080 (1999).
- Ji, P. *et al.* An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. *Mol. Cell* **16**, 47–58 (2004).
- Welch, P.J. & Wang, J.Y. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. *Cell* **75**, 779–790 (1993).
- Xiao, Z.X. *et al.* Interaction between the retinoblastoma protein and the oncoprotein MDM2. *Nature* **375**, 694–698 (1995).
- Lowe, E.D. *et al.* Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. *Biochemistry* **41**, 15625–15634 (2002).
- Schulman, B.A., Lindstrom, D.L. & Harlow, E. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. *Proc. Natl. Acad. Sci. USA* **95**, 10453–10458 (1998).
- Egloff, M.P., Cohen, P.T., Reinemer, P. & Barford, D. Crystal structure of the catalytic subunit of human protein phosphatase 1 and its complex with tungstate. *J. Mol. Biol.* **254**, 942–959 (1995).
- Goldberg, J. *et al.* Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. *Nature* **376**, 745–753 (1995).
- Tamrakar, S., Mittnacht, S. & Ludlow, J.W. Binding of select forms of pRB to protein phosphatase type 1 independent of catalytic activity. *Oncogene* **18**, 7803–7809 (1999).
- Meiselbach, H., Sticht, H. & Enz, R. Structural analysis of the protein phosphatase 1 docking motif: molecular description of binding specificities identifies interacting proteins. *Chem. Biol.* **13**, 49–59 (2006).
- Huang, H.J. *et al.* Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. *Science* **242**, 1563–1566 (1988).
- Hinds, P.W. *et al.* Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. *Cell* **70**, 993–1006 (1992).
- Zhu, L. *et al.* Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. *Genes Dev.* **7**, 1111–1125 (1993).
- Margolis, S.S. *et al.* PP1 control of M phase entry exerted through 14–3–3-regulated Cdc25 dephosphorylation. *EMBO J.* **22**, 5734–5745 (2003).
- Ferrell, J.E. Jr. Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs. *Trends Biochem. Sci.* **21**, 460–466 (1996).
- Goldbeter, A. & Koshland, D.E. Jr. An amplified sensitivity arising from covalent modification in biological systems. *Proc. Natl. Acad. Sci. USA* **78**, 6840–6844 (1981).
- Salazar, C. & Hofer, T. Competition effects shape the response sensitivity and kinetics of phosphorylation cycles in cell signaling. *Ann. NY Acad. Sci.* **1091**, 517–530 (2006).
- Thomson, M. & Gunawardena, J. Unlimited multistability in multisite phosphorylation systems. *Nature* **460**, 274–277 (2009).
- Tanoue, T., Adachi, M., Moriguchi, T. & Nishida, E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. *Nat. Cell Biol.* **2**, 110–116 (2000).

ONLINE METHODS

Protein expression and purification. Recombinant PP1c (α isoform) was expressed in *E. coli* using a *tac* promoter; 2 mM MnCl_2 was added to the media upon induction. Purification was best achieved using a salt-dependent PP1c-inhibitor-2 association⁴⁶. Full-length, human inhibitor-2 was expressed with an N-terminal hexahistidine tag in *E. coli*. Following cell lysis with 6 M urea, inhibitor-2 was bound to nickel sepharose beads and exchanged to a buffer containing 20 mM Tris, 50 mM NaCl, 15 mM imidazole, 0.4 mM MnCl_2 , 0.2 mM TCEP and 0.1 mM PMSF (pH 8.0). Cells expressing PP1c were lysed in this same buffer, the cleared lysate was passed over the immobilized inhibitor-2 and PP1c was eluted with lysis buffer containing 1 M NaCl. For crystallography, PP1c was further purified with a Superdex75 column (GE Healthcare) equilibrated in 20 mM Tris, 500 mM NaCl, 2 mM DTT, 0.4 mM MnCl_2 (pH 8.0). RbC, Rb₅₅₋₉₂₈, E2F1-DP1 (RbC binding domains) and Cdk2-CycA protein constructs were expressed and purified as described previously^{26,47,48}. The Rb constructs in both the calorimetry and kinetic experiments had N-terminal hexahistidine tags left intact. Cdk activating kinase from *Saccharomyces cerevisiae* (Cak) was expressed as a GST fusion protein in *E. coli* and purified with glutathione sepharose affinity chromatography.

Isothermal titration calorimetry. ITC experiments were performed with a VP-ITC instrument (MicroCal). Typically, 0.5–1 mM of each RbC construct or synthetic RbC peptide was titrated into a 25–50 μM solution of PP1c. Experiments were carried out at 25 °C in a buffer containing 25 mM Tris, 100 mM NaCl and 1 mM DTT (pH 8.0). Each reported binding constant is the average from 2 or 3 experiments, and the reported error is the s.d. of the K_d from these measurements.

Crystallization and structure determination. Purified PP1c was concentrated to 10 mg ml^{-1} after the Superdex75 column and synthetic Rb₈₇₀₋₈₈₂ peptide (Biopeptide Co., Inc.) was added in a 3:1 molar ratio. Crystals were grown using the hanging-drop vapor diffusion method at room temperature (22 °C). The crystallization buffer contained 100 mM HEPES, 200 mM MgCl_2 and 18% (w/v) PEG 4000 (pH 7.5) and was mixed in a 1:1 ratio with protein solution. Crystals grew with a needle morphology to dimensions of approximately 50 $\mu\text{m} \times 50 \mu\text{m} \times 500 \mu\text{m}$. Crystals were harvested by transferring to a solution containing 100 mM HEPES, 200 mM MgCl_2 , 20% (w/v) PEG 4000 and 20% (v/v) glycerol (pH 7.5) and flash freezing in liquid nitrogen. A molecular replacement solution was obtained using the PP1c-microcystin crystal structure (PDB 1FJM) as a search model³⁴. Further details regarding model building and refinement can be found in **Supplementary Methods**.

Phosphatase and kinase assays. Purified Cdk2-CycA was first activated by phosphorylation in a reaction containing 10% (w/w) GST-Cak, 10 mM MgCl_2 and 5 mM ATP. To prepare for the phosphatase assays, 1 mg of RbC was incubated with 0.25 mg of activated Cdk2-CycA for 1 h at room temperature in a buffer containing 50 mM HEPES, 100 mM NaCl, 10 mM MgCl_2 , 1 mM ATP and 5 μCi of ^{32}P -labeled ATP (pH 7.5). These reaction conditions give nearly quantitative phosphorylation of Cdk consensus sites in RbC⁴⁸. Reactions were quenched by addition of 8 M urea, and phosRbC was isolated with a nickel-nitrilotriacetic acid spin column (Qiagen). Phosphatase reactions were carried out at room temperature in a buffer containing 50 mM HEPES, 100 mM NaCl and 2 mM MnCl_2 (pH 7.5). Reactions were initiated by addition of enzyme. Aliquots were removed at the indicated time point and quenched by mixing with SDS-PAGE loading buffer.

For the phosphatase steady-state analysis, dephosphorylation assays were carried out at varying substrate concentrations. The initial rate at each concentration was determined from a linear fit of band intensities of the first 3 or 4 time points, and the corresponding fitting errors were assigned as the error of each rate measurement. Initial rates were fit as a function of substrate concentration with a simple Michaelis-Menten model to calculate the effective K_M and k_{cat} .

For kinase assays, 75 nM activated (phosphorylated with Cak) Cdk2-CycA, 20 μM E2F1-DP1 and 2 μM RbC substrates were mixed in a reaction at room temperature containing the kinase buffer described above and 20 μCi of ^{32}P -labeled ATP (pH 7.5). In kinase reactions with PP1c, PP1c was first inactivated by mixing in a 1:3 molar ratio with L,R-microcystin. An additional 25 μM microcystin was present in the competition reactions to ensure no residual PP1c activity (the IC_{50} for microcystin is ~ 1 nM). Phosphorimaging was done with a Typhoon Trio gel scanner (Amersham) and data was analyzed with the ImageQuant software package (Molecular Dynamics). Kinetic data were fit with a first-order rate law using Kaleidagraph (Synergy Software). The reported error of each kinetic parameter is the fitting error.

Cell-cycle arrest experiments. We transfected 1×10^6 proliferating Saos-2 cells with 0.75 μg of CMV-Rb (0.5 μg in **Fig. 5b**), 1 μg of CMV-CD20 (used to mark transfected cells in flow cytometry analysis) and 6 μg of CMV-bGal, using Eugene 6 (Roche). Where indicated, 1 μg of CMV-HA-cdk2, 1 μg of CMV-CycA and 4 μg of CMV-myc-PP1c were added, and the appropriate amount of CMV-bGal was omitted to maintain uniform DNA concentrations. We analyzed cells 3 d following transfection by flow cytometry as described previously⁴⁹.

C33A cells were transfected with 10 μg of CMV-Rb, 2.5 μg of CMV-HA-cdk2, 2.5 μg of CMV CycA and 2.5 to 10 μg of CMV-myc-PP1c; CMV- β Gal was included where necessary to obtain a final quantity of 25 μg . Transfections were performed by Ca_2PO_4 precipitation. Cells were harvested after 2 d, and nuclear lysates were prepared for SDS-PAGE and western blotting as described⁵⁰. Rb was detected with monoclonal antibody G3-245 (BD Pharmingen) and anti-phosphoserine 807/811 antibodies from Cell Signaling.

For immunoprecipitation experiments, extracts were prepared as described above from Saos-2 cells transfected with Eugene HD (Roche). CV-1 cells were isolated by mitotic shakeoff from cultures that were first blocked in S phase with 2.5 mg ml^{-1} aphidicolin for 24 h then released for 16 h to enrich for mitotic cells. Immunoprecipitations were carried out using monoclonal antibody Rb4.1 (Developmental Studies Hybridoma Bank, University of Iowa) against Rb. Extracts and immunoprecipitated proteins were analyzed by SDS-PAGE alongside recombinant PP1c and GST-Rb₃₈₀₋₉₂₈ controls. Rb and PP1 were detected on western blots by Rb4.1 and sc-7482 (Santa Cruz), respectively. Standard curves to determine protein quantities were generated by using ImageJ software (US National Institutes of Health) to quantitate band intensities.

46. Zhang, Z., Zhao, S., Zirattu, S.D., Bai, G. & Lee, E.Y. Expression of recombinant inhibitor-2 in *E. coli* and its utilization for the affinity chromatography of protein phosphatase-1. *Arch. Biochem. Biophys.* **308**, 37–41 (1994).
47. Russo, A.A. Purification and reconstitution of cyclin-dependent kinase 2 in four states of activity. *Methods Enzymol.* **283**, 3–12 (1997).
48. Burke, J.R., Deshong, A.J., Pelton, J.G. & Rubin, S.M. Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. *J. Biol. Chem.* **285**, 16286–16293 (2010).
49. van den Heuvel, S. & Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle control. *Science* **262**, 2050–2054 (1993).
50. Seifried, L.A. *et al.* pRB-E2F1 complexes are resistant to adenovirus E1A-mediated disruption. *J. Virol.* **82**, 4511–4520 (2008).